June 6-9, 2016 | San Francisco, CA

Partnering & Education: Monday – Thursday

Exhibition: Tuesday – Thursday

Double Helix Sponsor


Schedule at a glance

Registration Rates

Join the Mailing List



BIO Buzz - Official Show Daily, Brought to you by Alexandria

Health Care


Dave Thomas, Senior Director of Industry Research and Policy Analysis, BIO. BIO Buzz Center 2015
Pamela Gavin, COO, National Organization for Rare Disorders at the BIO Buzz Center 2015
Dr. Eric Topol, Director, Scripps Translational Science Institute, at the BIO Buzz Center 2015
Paul Hastings, OncoMed Pharmaceuticals at the 2015 BIO International Convention
Seema Kumar, Johnson & Johnson at the 2015 BIO International Convention
Dr. Barry Springer, VP of Strategy, Janssen BioTherapeutics, at the BIO Buzz Center 2015
Kimberly Wintenberg, Advanced Plasma Products at the 2015 BIO International Convention
Dr. Francis Kateh, Deputy Minister of Health & CMO, Liberia, at the BIO Buzz Center 2015
Marc Boutin, National Health Council at the 2015 BIO International Convention
Ted Buckley, Head of Government Relations and Public Affairs, Shire Pharmaceuticals
Dr. John Watson, UK Department of Health at the 2015 BIO International Convention
Dr. Robin Robinson, BARDA at the 2015 BIO International Convention

Articles from BioTechNow

Mesothelioma: Once Hopeless Cancer, on the Verge of Promising Advances

Publish Date: 10/26/2015, Created By: BIOtechNOW Editor

Mesothelioma, the word, (pronounced mez-uh-thee-lee-oh-muh) is often much better known than the illness it represents. The legal issues surrounding this cancer make mesothelioma, the most expensive keyword on Google (while most keywords cost pennies, the keyword mesothelioma can cost over $300 per click). Mesothelioma, the illness, is a cancer that most often affects the lining of the lung or abdomen; it has no cure and treatment options for patients are few. Prognosis is generally considered ...

Read More >

Roll Call: Patient-Centeredness, Comparative Effectiveness, and Value

Publish Date: 10/20/2015, Created By: BIOtechNOW Editor

In Roll Call, Tony Coelho former House Majority Whip, Chairman of the Partnership to Improve Patient Care (PIPC) and author of the Americans with Disabilities Act (ADA) discussed the need for a patient-centered approach to healthcare. Coelho says: “Policymakers talk about the “value” of treatments as if there is one value algorithm that applies to all patients equally. While that may be true in academia, in the real world value is personal. Research on treatment ...

Read More >

Wall Street Journal: Patients Deserve Better

Publish Date: 10/14/2015, Created By: Jim Greenwood

In case you missed it, The Wall Street Journal published my Letter to the Editor this morning.  I make the point that the problem isn’t innovative new treatments from America’s biopharma industry but rather the complex web of health-insurance schemes patients must navigate to access needed medicines. Here is the text of the letter: “Innovative treatments and cures have radically transformed how we treat disease—saving and improving lives and providing tremendous benefits to patients and ...

Read More >

WSJ Article Cherry Picks Cost, Ignores Value of Medicines

Publish Date: 10/6/2015, Created By: Jim Greenwood

Today’s Wall Street Journal story, “Price Increases Drive Drug Firms’ Revenue” reaffirms that old chestnut, “…a little information is a dangerous thing…”  When speaking to the complexities of the costs and benefits of America’s healthcare system, a publication like the Wall Street Journal should not cherry pick one aspect of that system to cover while ignoring the rest. Unfortunately and uncharacteristically, in this case, the paper focused on particular costs while ignoring value. In fact, ...

Read More >

Wall Street Journal: The Assault on Drug Innovation

Publish Date: 9/23/2015, Created By: Daniel Seaton

Today, the Wall Street Journal published an editorial commenting on yesterday’s proposed plan by Secretary Hillary Clinton’s campaign to dramatically increase intrusive government regulation of our industry. BIO shared many of the concerns raised by this editorial, concerns which were noted in our statement yesterday. To put into perspective the potential consequences of that proposal, the editorial noted as an example that “Inside of a decade or two, metastatic cancer may become a chronic condition and chemotherapy a relic.” Breakthroughs ...

Read More >

Ezekiel Emanuel’s Flawed Solution

Publish Date: 9/9/2015, Created By: Jim Greenwood

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug Prices.” The piece is problematic in many respects, but we agree with one of his primary contentions: in discussions about drug prices, value is the real issue. This point was nicely made in a recent Times piece, where it quoted Crystal Bedford, whose five year old daughter, Marley, suffers from a rare genetic disease, Rhizomelic Chondrodysplasia Punctata (RCPD). A treatment ...

Read More >

Rx Response Changes Name to Healthcare Ready

Publish Date: 8/12/2015, Created By: Tracy Cooley

Yesterday, Rx Response announced that its name will be changing to Healthcare Ready. For nearly nine years, Rx Response has helped protect patients’ continued access to medicines in more than 55 different disasters. The rationale for the name change is to better reflect its shifting mission of providing assistance in areas of healthcare outside of medicines and pharmacy. The group has gained significant experience and expertise in ‘coordinating the healthcare system and the public sector during disasters, ...

Read More >

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

Publish Date: 6/18/2015, Created By: BIOtechNOW Editor

In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in total transactions, including $53 billion in partnering deals, $16.5 billion in venture investments and 133 IPOs. According to the 2015 Campbell Alliance Dealmakers’ Intentions Study, 2015 is shaping up to be the year of historic M&A in the biopharmaceutical sector, driven in part by greater access to capital. The partnering numbers at BIO 2015 further indicate that the appetite for ...

Read More >

The Next Step: How Companies Build Successful Therapeutic Franchises from the Ground Up

Publish Date: 6/18/2015, Created By: BIOtechNOW Editor

Building a new franchise in a therapeutic from scratch poses a host of challenges, from whether to take the risk of entering a new area at all to whether and how to partner strategically with another company. It’s a challenge for both the biggest biopharma companies and emerging biotechs to evaluate how and when to enter new therapeutic areas and to try to ensure that their efforts will not only help patients in need but ...

Read More >

Wednesday Recap of BIO 2015: What the Official Bloggers Have to Say

Publish Date: 6/17/2015, Created By: Kathryn Mueller

Everyday our BIO Official Bloggers, writers who are on top of the biotechnology beat, release statements about their experience at the BIO International Convention. Here is what they want to share with you today: Scrip Intelligence By Lisa LaMotta Roche’s strong deal-making position is at least partly due to its acquisition of Genentech, but partnering head Sophie Kornowski-Bonnet explained that the firm is more interested in looking for drugs than bolt-on companies. Read more…   ...

Read More >

Thank you to our 2016 Sponsors

Double Helix Sponsors

Helix Sponsors

Premier Sponsors